BioLargo, Inc. (BLGO)
Full history for every metric is available with a Kvantra account
No price history available.
Key financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 2 | 3 | 6 | 12 | 18 | 8 | 4 | 5 |
| Operating profit | $m | -15 | -18 | ||||||
| Net profit | $m | -10 | -7 | -4 | -4 | -2 | -12 | -14 | -15 |
| EPS reported | $ | -0.04 | -0.05 | ||||||
| Operating cashflow per share | $ | -0.03 | -0.03 | ||||||
| Capex per share | $ | 0.00 | 0.00 | ||||||
| FCF per share | $ | -0.03 | -0.03 | ||||||
| Free cash flow | $m | -8 | -10 | ||||||
| Net debt | $m | -2 | 3 | ||||||
| Book value equity | $m | 4 | -2 | ||||||
| Book value per share | $ | 0.01 | -0.01 | ||||||
| Number of shares | m | 306.95 | 320.98 | ||||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | - | - | ||||||
| P/B LTM | x | 14.00 | -30.55 | ||||||
| P/S LTM | x | 7.29 | 13.86 | ||||||
| P/FCF LTM | x | -6.78 | -5.46 | ||||||
| EV/EBITDA LTM | x | -3.86 | -3.17 | ||||||
| EV/Sales LTM | x | 7.24 | 8.11 | ||||||
| Earnings Yield LTM | % | -20.82% | -50.14% | ||||||
| FCF Yield | % | -14.75% | -18.33% | ||||||
| Quality | |||||||||
| ROE | % | -291.44% | -548.88% | ||||||
| ROIC | % | -2.95% | -4.94% | ||||||
| Operating margin | % | -1.91% | -4.44% | ||||||
| Gross margin | % | +43.86% | +39.93% | ||||||
| FCF/Sales | % | -107.44% | -253.99% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | - | - | ||||||
| Sales Growth YoY | % | -56.32% | -77.04% | ||||||
| Net Income Growth YoY | % | - | - | ||||||
| FCF Growth | % | - | - | ||||||
| Operating Profit Growth | % | - | - | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | +0.61% | 0.00% | ||||||
| Dividend Growth | % | -2.31% | +38.91% | ||||||
| Payout Ratio | % | -2.94% | -3.42% | ||||||
| FCF/Debt | x | -2.37 | -1.62 | ||||||
| Net Debt/EBITDA | x | 0.03 | -0.24 | ||||||
| EBIT/Net interest | x | -27.48 | -20.35 | ||||||
| Net debt/market cap | % | +3.67% | +18.86% | ||||||
| Net debt/Equity | x | -0.45 | -1.58 | ||||||
| Gross debt/equity | x | 0.87 | -3.45 | ||||||
Price target estimates
Based on consensus from external analysts. Not Kvantra's opinion.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
ESG
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| ESG-score | |||
| Environmental score | |||
| Social score | |||
| Governance score | |||
| Risk rating |
Company overview
BioLargo, Inc. pioneers the invention, development, and commercialization of sophisticated platform technologies. The company is dedicated to tackling critical environmental challenges, such as per- and polyfluoroalkyl substances (PFAS) contamination, advanced water and wastewater purification, managing industrial odors and volatile organic compounds (VOCs), enhancing air quality, and controlling infections. Backed by numerous issued patents, BioLargo maintains a robust product pipeline and extends its expertise through comprehensive environmental engineering services. Among its notable innovations are the Advanced Oxidation system, a water treatment solution generating potent oxidative and energetic iodine species; the Aqueous Electrostatic Concentrator, specifically designed for eliminating PFAS from water; CupriDyne Clean industrial products, which effectively neutralize stubborn odors and VOCs across various industrial settings; and specialized advanced wound care products. Established in 1991, BioLargo, Inc. is headquartered in Westminster, California.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
No price history available.
Consensus from external analysts. Not Kvantra's opinion.
Based on consensus from external analysts. Not Kvantra's opinion.
BioLargo, Inc. pioneers the invention, development, and commercialization of sophisticated platform technologies. The company is dedicated to tackling critical environmental challenges, such as per- and polyfluoroalkyl substances (PFAS) contamination, advanced water and wastewater purification, managing industrial odors and volatile organic compounds (VOCs), enhancing air quality, and controlling infections. Backed by numerous issued patents, BioLargo maintains a robust product pipeline and extends its expertise through comprehensive environmental engineering services. Among its notable innovations are the Advanced Oxidation system, a water treatment solution generating potent oxidative and energetic iodine species; the Aqueous Electrostatic Concentrator, specifically designed for eliminating PFAS from water; CupriDyne Clean industrial products, which effectively neutralize stubborn odors and VOCs across various industrial settings; and specialized advanced wound care products. Established in 1991, BioLargo, Inc. is headquartered in Westminster, California.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free